Genomic Classification and Individualized Prognosis in Multiple Myeloma
Journal of Clinical Oncology · 10.04.2024 · 42 (11) · 1229-1240
DOI: 10.1200/jco.23.01277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2024. Verfasst von Francesco Maura und 36 weiteren Autor:innen. Beteiligte Einrichtung: Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 142-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE Outcomes for patients with newly diagnosed multiple myeloma (NDMM) are heterogenous, with overall survival (OS) ranging from months to over 10 years. METHODS To decipher and predict the molecular and clinical heterogeneity of NDMM, we assembled a series of 1,933 patients with available clinical, genomic, and therapeutic data. RESULTS Leveraging a comprehensive catalog of genomic drivers, we identified 12 groups, expanding on previous gene expression–based molecular classifications. To build a model predicting individualized risk in NDMM (IRMMa), we integrated clinical, genomic, and treatment variables. To correct for time-dependent variables, including high-dose melphalan followed by autologous stem-cell transplantation (HDM-ASCT), and maintenance therapy, a multi-state model was designed. The IRMMa model accuracy was significantly higher than all comparator prognostic models, with a c-index for OS of 0.726, compared with International Staging System (ISS; 0.61), revised-ISS (0.572), and R2-ISS (0.625). Integral to model accuracy was 20 genomic features, including 1q21 gain/amp, del 1p, TP53 loss, NSD2 translocations, APOBEC mutational signatures, and copy-number signatures (reflecting the complex structural variant chromothripsis). IRMMa accuracy and superiority compared with other prognostic models were validated on 256 patients enrolled in the GMMG-HD6 (ClinicalTrials.gov identifier: NCT02495922 ) clinical trial. Individualized patient risks were significantly affected across the 12 genomic groups by different treatment strategies (ie, treatment variance), which was used to identify patients for whom HDM-ASCT is particularly effective versus patients for whom the impact is limited. CONCLUSION Integrating clinical, demographic, genomic, and therapeutic data, to our knowledge, we have developed the first individualized risk-prediction model enabling personally tailored therapeutic decisions for patients with NDMM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL.
- Heidelberg Myeloma Center, Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany.
- Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY.
ORCID-Profile: Francesco Maura, Arjun Raj Rajanna, Andriy Derkach, Kylee Maclachlan, Michael Durante, Benjamin Diamond, Faith Davies, Eileen M Boyle, Brian Walker, Malin Hultcrantz, Jamie K Teer, Erin M Siegel, Graham H Jackson, Martin Kaiser, Charlotte Pawlyn, Gordon Cook, Dickran Kazandjian, Marta Chesi, Leif Bergsagel, Elias K Mai, Hartmut Goldschmidt, Katja C Weisel, Roland Fenk, Marc S Raab, Fritz Van Rhee, Saad Usmani, Kenneth H Shain, Niels Weinhold, Ola Landgren
Förderung
- NCI NIH HHS
Zitieren
APA
Maura, F., Rajanna, A. R., Ziccheddu, B., Poos, A. M., Derkach, A., Maclachlan, K., Durante, M., Diamond, B., Papadimitriou, M., Davies, F., Boyle, E. M., Walker, B., Hultcrantz, M., Silva, A., Hampton, O., Teer, J. K., Siegel, E. M., Bolli, N., Jackson, G. H., …, & Landgren, O. (2024). Genomic Classification and Individualized Prognosis in Multiple Myeloma. Journal of Clinical Oncology, 42(11), 1229-1240. https://doi.org/10.1200/jco.23.01277
Vancouver
Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, et al. Genomic Classification and Individualized Prognosis in Multiple Myeloma. Journal of Clinical Oncology. 2024;42(11):1229-1240. doi:10.1200/jco.23.01277
BibTeX
@article{Maura2024,
author = {Maura, Francesco and Rajanna, Arjun Raj and Ziccheddu, Bachisio and Poos, Alexandra M and Derkach, Andriy and Maclachlan, Kylee and Durante, Michael and Diamond, Benjamin and Papadimitriou, Marios and Davies, Faith and Boyle, Eileen M and Walker, Brian and Hultcrantz, Malin and Silva, Ariosto and Hampton, Oliver and Teer, Jamie K and Siegel, Erin M and Bolli, Niccolò and Jackson, Graham H and Kaiser, Martin and Pawlyn, Charlotte and Cook, Gordon and Kazandjian, Dickran and Stein, Caleb and Chesi, Marta and Bergsagel, Leif and Mai, Elias K and Goldschmidt, Hartmut and Weisel, Katja C and Fenk, Roland and Raab, Marc S and Van Rhee, Fritz and Usmani, Saad and Shain, Kenneth H and Weinhold, Niels and Morgan, Gareth and Landgren, Ola},
title = {Genomic Classification and Individualized Prognosis in Multiple Myeloma},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {11},
pages = {1229--1240},
doi = {10.1200/jco.23.01277}
}
EUVIMED